Rahila Sardar PhD.

As the founder and CEO of Vgenomics, Dr. Rahila Sardar is dedicated to driving strategic initiatives aimed at innovating in the realm of accessible diagnostics and therapeutics for rare genetic diseases. Her journey began as a Senior Research Fellow at ICMR in New Delhi, where she made significant strides in identifying novel drug targets for malaria, marking the beginning of her impactful career in medical research.

Crossing international borders, she served as a Consultant at Alladapt Immunotherapeutics in the USA, where she focused on identifying cross-reactive peptides from food allergens, showcasing her versatility and expertise in diverse areas of medical science.

During her tenure at ICGEB in New Delhi, Dr. Sardar played a pivotal role in unravelling drug resistance mechanisms in tuberculosis while also spearheading projects in biofuel production and algal genome assembly, demonstrating her multifaceted approach to addressing complex healthcare challenges. As a guest faculty member at DPSRU in New Delhi, Dr. Sardar shares her knowledge and expertise with future AI experts in Medicine, bridging the gap between biology and technology and shaping the minds of tomorrow’s healthcare innovators.

Research articles

Dr. Sardar’s contributions have been recognized through publications in prestigious journals such as Cell Press, Oxford, and Frontiers, solidifying her reputation as a thought leader in the field. Notably, she was among the first researchers to publish a paper on COVID-19 in India, underscoring her commitment to addressing pressing global health concerns.

Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis

The ongoing pandemic of the coronavirus disease 2019 (COVID–19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)….

Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies

We have performed an integrative analysis of SARS-CoV-2 genome sequences from different countries. Apart from mutational analysis, we have predicted host antiviral miRNAs targeting virus genes…

Identification of novel SARS-CoV-2 drug targets by host microRNAs and transcription factors co-regulatory interaction network analysis

Understanding the host regulatory mechanisms opposing virus infection and virulence can provide actionable insights to identify novel therapeutics against severe acute respiratory syndrome coronavirus…

Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples

While our battle with the COVID-19 pandemic continues, a multitude of Omics data have been generated from patient samples in various studies. Translation of these data into clinical interventions against COVID-19 remains to be accomplished…

Machine learning assisted prediction of prognostic biomarkers associated with COVID-19, using clinical and proteomics data

With the availability of COVID-19-related clinical data, healthcare researchers can now explore the potential of computational technologies such as artificial intelligence (AI) and machine learning (ML) to discover biomarkers for accurate detection, early diagnosis, and prognosis for the management of COVID-19…

Dataset of mutational analysis, miRNAs targeting SARS-CoV-2 genes and host gene expression in SARS-CoV and SARS-CoV-2 infections

The identification of host-miRNAs targeting mutated virus genes is crucial to understand the miRNA mediated host-defense mechanism in virus infections. To understand the mechanism in COVID-19 infections, we collected genome sequences of SARS-CoV-2 with its metadata from the GISAID database (submitted till April 2020) and identified mutational changes in the sequences.

A genome-wide analysis of coatomer protein (COP) subunits of apicomplexan parasites and their evolutionary relationships

Protein secretion is an essential process in all eukaryotes including organisms belonging to the phylum Apicomplexa, which includes many intracellular parasites. The apicomplexan parasites possess a specialized collection of secretory organelles that release a number of proteins to facilitate the invasion of host cells and some of these proteins also participate in immune evasion…

Natural selection plays a significant role in governing the codon usage bias in the novel SARS-CoV-2 variants of concern (VOC)

The ongoing prevailing COVID-19 pandemic caused by SARS-CoV-2 is becoming one of the major global health concerns worldwide. The SARS-CoV-2 genome encodes spike (S) glycoprotein that plays a very crucial role in viral entry into the host cell via binding of its receptor binding domain (RBD) to the host angiotensin converting enzyme 2 (ACE2) receptor….

In-silico profiling and structural insights into the impact of nSNPs in the P. falciparum acetyl-CoA transporter gene to understand the mechanism of drug resistance in malaria

The continuous emergence of resistance to the available drugs poses major constraints in the development of effective therapeutics against malaria. Malaria drug resistance has been attributed to be the manifestation of numerous factors…

ApicoTFdb: the comprehensive web repository of apicomplexan transcription factors and transcription-associated co-factors

Despite significant progress in apicomplexan genome sequencing and genomics, the current list of experimentally validated transcription factors (TFs) in these genomes is incomplete and mainly consists of AP2 family of proteins, with only a limited number of non-AP2 family TFs and transcription-associated co-factors (TcoFs).

Comparative analysis of codon usage patterns in SARS-CoV-2, its mutants and other respiratory viruses

The Coronavirus disease 2019 (COVID-19) outbreak caused by Severe Acute Respiratory Syndrome Coronavirus 2 virus (SARS-CoV-2) poses a worldwide human health crisis, causing respiratory illness with a high mortality rate. To investigate the factors governing codon usage bias in all the respiratory viruses…

Bioinformatics of Genome Annotation

After performing the genome assembly with adaptor trimming and filtering for good quality sequences, the next step is assigning biological information to the raw sequence data called genome annotation such as function, pathway, location, size, molecular weight and other attributes.  This includes providing annotation to protein-coding  genes as well as non-coding genes…

Identification of transcription hubs that control lipid metabolism and carbon concentrating mechanism in model microalgae chlamydomonas reinhardtii using regulatory networks: Regulatory networks hubs in C. reinhardtii that control lipid and carbon concentrating metabolic pathways

Chlamydomonas reinhardtii is the most extensively studied eukaryotic model microalgae having essential biological pathways such as biomass production, photosynthesis, carbon concentrating mechanisms…

Meta-analysis of orthogonal OMICs data from COVID-19 patients unveils prognostic markers and antiviral factors

Coronavirus disease 2019 (COVID-19) pandemic has lasted more than a year since its first case in December 2019 and yet its social and economic burden continues to grow. While a tremendous amount of OMICs data has been generated from COVID-19 patient samples, the host antiviral response and markers of disease progression remain to be completely delineated. In this study, we have conducted a meta-analysis of published transcriptome and proteome profiles of the nasal swab…

Comparative Genomics of Two AT-Rich Protozoans Dictyostelium Discoideum and Plasmodium Falciparum Reveals Conserved as Well as Distinct Regulatory Pathways Crucial for Exploring Novel Therapeutic Targets for Malaria

Malaria is a serious public health problem, especially in African and Asian subcontinents. Plasmodium falciparum causes cerebral malaria, the most severe form of malaria. This parasite has gained widespread resistance against many of the frontline anti-malarial drugs…

With a decade of diverse experience under his belt, Sameer Malik, an alumnus of the Delhi School of Economics, brings a robust blend of business strategy, finance, operations, and sales expertise to Vgenomics. From kick starting his career at KPMG to founding and scaling an e-commerce startup to over $1.5 million in annual revenues, and further contributing to the startup ecosystem through his involvement in Startup Nexus and Token Amigo, Sameer has navigated through various industries, consistently playing to his strategic and operational strengths. His rich entrepreneurial journey and strategic acumen are now channeled towards advancing Vgenomics' mission in the realm of rare inborn diseases diagnostics and therapeutic solutions.

A translational biologist based in Silicon Valley, Dr. Lal brings her expertise in data science, translational medicine, clinical biomarker, and CDx implementation across all phases of clinical trials development to Vgenomics. With over 150 patents to her name, she has substantial experience in regulatory interactions with both the drug and device divisions of the FDA, and companion diagnostics (Dx) programs.

After earning her doctorate from International Center of Genetic Engineering and Biotechnology (ICGEB), Dr. Sardar embarked on a mission to transform her research findings into practical applications that could benefit rare disease patients globally. She noticed a gap in dedicated solutions for the burgeoning hub of rare diseases in India, particularly those affecting children, and co-founded Vgenomics with Dr. Preeti to develop affordable diagnostics and therapeutic solutions.

Open chat
✉ Hey! Need Help?
Can we help you?